| Revenue growth | 14.1% YoY in Q1 FY27 |
|---|---|
| Margins | Gross margin expanded to 46.5%; EBITDA margin slightly down |
| Demand visibility | Strong; 200+ product registrations in pipeline |
| Management confidence | High; citing improved business mix and strategic priorities |
Growth
Q1 FY27 revenue grew 14% to ₹80.68 Cr; PAT surged 347% to ₹1.29 Cr; Gross margins expanded 241 bps.
Outlook
Targeting top-2 positions in frontier markets; expansion into Ecuador and Chile; scaling new Hyderabad facility for better margins.
Risks
Old FY26 results showed 7.7% revenue decline; transition from asset-light to asset-heavy manufacturing carries execution risks.
Investor Presentation filed with NSE, NSE: BALAXI. Summary written with AI assistance from the document.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.38
- Market cap
- ₹123.5 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 51.0×Sector 47.3×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.3 Cr · +333.3% YoY
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report forms part of the company's Annual Report.